NABNEC: A Randomised Phase II Study Of Nab-paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas [ 2016 - ]

Research Grant

Researchers: A/Pr Mustafa Khasraw (Principal investigator) ,  A/Pr Lara Lipton ,  A/Pr Michael Michael ,  Dr Lorraine Chantrill ,  Dr Michael Christie
View all 9 related researchers

Brief description Patients with advanced neuroendocrine carcinomas (NEC) have one of the poorest cancer outcomes. So far, no randomised trials have been done to confirm NEC treatment. Current NEC chemotherapy is etoposide & carboplatin (EC), based on lung cancer trials. The NABNEC study will use a new drug, nab-paclitaxel, with carboplatin or EC, collect PET scan, tumour & blood samples result to help understand how treatment works and to ultimately improve NEC patients’ health and progress future research.

Funding Amount $1,393,083.00

Funding Scheme Project Grants

Notes Standard Project Grant